The document summarizes the validation of the TOYO Anti-HCV Test for detecting antibodies to HCV. It assessed the test's sensitivity using 100 samples that were confirmed positive by other methods, finding the TOYO test identified all 100 correctly. It assessed specificity using 100 samples that were confirmed negative, finding the TOYO test identified all 100 correctly. One sample showed discrepant results between membrane-based and plastic-based technologies, demonstrating a difference between testing methods. The validation concluded the TOYO Anti-HCV Test showed 100% sensitivity and specificity.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by...HK HuZef
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by US-FDA for USA
Due to the highly contagious nature and global
health crises, SARS-CoV-2 has been designated
as a pandemic by the World Health Organization
(WHO) and continues to have devastating
impacts on healthcare systems and the world
economy including the U.S.
To effectively end the SARS-CoV-2 pandemic,
systematic screening and detection of clinical
COVID-19 cases is critical. An effective screening
regimen in a workplace, campus or other
community setting can be established using
the quick results provided by antigen tests.
As an intended point-of-care (POC) designated
test with a 10 min processing time, CareStart™
COVID-19 Antigen Test allows effective screening
of COVID-19 infection on a large scale.
Features
( Lateral flow assay
( No equipment required
( Rapid results within 10 minutes
( Minimally invasive specimen collection
(nasopharyngeal)
( Intended at POC setting by
medical professionals
Clinical Features
( Detect SARS-CoV-2 nucleocapsid
protein antigen with ultra high
performance
( Identify acute infection with high
sensitivity and 100% specificity
Test Principles
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were
tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results.
Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the
CareStart™ COVID-19 Antigen.
High-dose Hook Effect
The CareStart™ COVID-19 Antigen was tested up to 105 TCID50/ml of heat-inactivated SARSCoV-2 strain and no high-dose hook effect was observed.
Point of Care Use
The CareStart™ COVID-19 Antigen was demonstrated at near patient or Point of Care (POC)
testing that non-laboratory personnel can perform the test accurately in the intended use
environment. In addition, the robust use of the CareStart™ COVID-19 Antigen for near patient
or Point of Care (POC) testing was demonstrated by thirteen (13) Flex studies.
Technical Support
For questions, or to report a problem, please call Technical Support at +1-888-898-1270
(Available Hours: Mon. to Fri.: 8 a.m. – 5 p.m.) or TShelp@accessbio.net (24/7 available).
Test system problems may also be reported to the FDA using the MedWatch reporting system
(phone: 1-800 FDA-1088; fax: 1-800 FDA-1078: or http://www.fda.gov/medwatch)
For Emergency Use Authorization (EUA) Only
The CareStartTM COVID-19 Antigen test is a lateral ow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2
in nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within ve days of symptom onset.
IMPORTANT!
- Refer to the Package Insert for Warnings and Precautions, Specimen Collection Procedures, Storage and Handling Conditions, and Quality Control Recommendations.
- Warning and Precautions - All kit components can be discarded as Biohazard waste according to local guidelines. Refer to the product safety data sheet for risk and safety phrases and disposal information.
- Biotin Interference: False negative results may occur in patients who have indicated or whose clinical status or history would indicate they are currently taking high doses of biotin (> 10 mg per day). Biotin
levels of 2.5 µg/mL have been demonstrated to result in false negative test results.
- The extracted sample must be used within 4 hours of preparation when stored at room temperature.
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html
Access bio care antigen US=FDA EUA Approvel LetterHK HuZef
est Principles
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by...HK HuZef
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by US-FDA for USA
Due to the highly contagious nature and global
health crises, SARS-CoV-2 has been designated
as a pandemic by the World Health Organization
(WHO) and continues to have devastating
impacts on healthcare systems and the world
economy including the U.S.
To effectively end the SARS-CoV-2 pandemic,
systematic screening and detection of clinical
COVID-19 cases is critical. An effective screening
regimen in a workplace, campus or other
community setting can be established using
the quick results provided by antigen tests.
As an intended point-of-care (POC) designated
test with a 10 min processing time, CareStart™
COVID-19 Antigen Test allows effective screening
of COVID-19 infection on a large scale.
Features
( Lateral flow assay
( No equipment required
( Rapid results within 10 minutes
( Minimally invasive specimen collection
(nasopharyngeal)
( Intended at POC setting by
medical professionals
Clinical Features
( Detect SARS-CoV-2 nucleocapsid
protein antigen with ultra high
performance
( Identify acute infection with high
sensitivity and 100% specificity
Test Principles
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were
tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results.
Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the
CareStart™ COVID-19 Antigen.
High-dose Hook Effect
The CareStart™ COVID-19 Antigen was tested up to 105 TCID50/ml of heat-inactivated SARSCoV-2 strain and no high-dose hook effect was observed.
Point of Care Use
The CareStart™ COVID-19 Antigen was demonstrated at near patient or Point of Care (POC)
testing that non-laboratory personnel can perform the test accurately in the intended use
environment. In addition, the robust use of the CareStart™ COVID-19 Antigen for near patient
or Point of Care (POC) testing was demonstrated by thirteen (13) Flex studies.
Technical Support
For questions, or to report a problem, please call Technical Support at +1-888-898-1270
(Available Hours: Mon. to Fri.: 8 a.m. – 5 p.m.) or TShelp@accessbio.net (24/7 available).
Test system problems may also be reported to the FDA using the MedWatch reporting system
(phone: 1-800 FDA-1088; fax: 1-800 FDA-1078: or http://www.fda.gov/medwatch)
For Emergency Use Authorization (EUA) Only
The CareStartTM COVID-19 Antigen test is a lateral ow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2
in nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within ve days of symptom onset.
IMPORTANT!
- Refer to the Package Insert for Warnings and Precautions, Specimen Collection Procedures, Storage and Handling Conditions, and Quality Control Recommendations.
- Warning and Precautions - All kit components can be discarded as Biohazard waste according to local guidelines. Refer to the product safety data sheet for risk and safety phrases and disposal information.
- Biotin Interference: False negative results may occur in patients who have indicated or whose clinical status or history would indicate they are currently taking high doses of biotin (> 10 mg per day). Biotin
levels of 2.5 µg/mL have been demonstrated to result in false negative test results.
- The extracted sample must be used within 4 hours of preparation when stored at room temperature.
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html
Access bio care antigen US=FDA EUA Approvel LetterHK HuZef
est Principles
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
Regulatory oversight of genetic testing in Canada: Health Canada perspectiveMaRS Discovery District
Speaker: Patrice Sarrazin, PhD, Senior Scientific Evaluator, In Vitro Diagnostic Devices, Medical Devices Bureau, Therapeutic Product Directorate, Health Canada. Patrice discusses Health Canada's perspective on genetic testing as well as policy and regulation in Canada.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsHK HuZef
LYHER Covid-19 IgG/IgM Antibody Rapid test Kits, US FDA EUA Approval Certificate.
This product, CFUS Anti-SARS-CoV-2 Reference Material Kit Series 1000, is formulated for use with the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit under the Emergency Use Authorization only.
Sepsis biomarkers an update by Dr Puneet JainPuneet Jain
sepsis biomarkers play a crucial role in decision making and management of sepsis cases. these biomarkers can be diagnostic, prognostic or theranostic. CRP and Procalcitonin are most widely used and studied biomarkers.
Regulatory oversight of genetic testing in Canada: Health Canada perspectiveMaRS Discovery District
Speaker: Patrice Sarrazin, PhD, Senior Scientific Evaluator, In Vitro Diagnostic Devices, Medical Devices Bureau, Therapeutic Product Directorate, Health Canada. Patrice discusses Health Canada's perspective on genetic testing as well as policy and regulation in Canada.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsHK HuZef
LYHER Covid-19 IgG/IgM Antibody Rapid test Kits, US FDA EUA Approval Certificate.
This product, CFUS Anti-SARS-CoV-2 Reference Material Kit Series 1000, is formulated for use with the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit under the Emergency Use Authorization only.
Sepsis biomarkers an update by Dr Puneet JainPuneet Jain
sepsis biomarkers play a crucial role in decision making and management of sepsis cases. these biomarkers can be diagnostic, prognostic or theranostic. CRP and Procalcitonin are most widely used and studied biomarkers.
Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
3. • Accredited under ISO / IEC 17043 “Conformity assessment ‐ general
requirements for professional testing” (accreditation certificate No. KG
417/КЦА.ППТ. 001)
• Scope of accreditation: programs for testing the quality of diagnosis of infectious
diseases using ELISA, ICT (ET), IB, PCR, RPGA. RPR, RMP, RA: HIV, HBV, HCV, HAV,
IOP, syphilis; brucellosis; HSV; CMV; chlamydia; toxoplasma; ureaplasma,
mycoplasma. Accreditation body – Kyrgyz Center for Accreditation
• USA CDC qualified preparedness for the International Accreditation
ISO/IEC 17043 under American Association for Laboratory
Accreditation (AALA) (pending for the visit 2018)
Validation Conducted by Reference Laboratory of RCQCLD of the
Ministry of Health of the Kyrgyz Republic, Scientific and Production
Association "Preventive Medicine
Lab description and credentials 2
6. Methods and interpretations
• Internal tests control – according the instruction the tests were
considered valid when any visible red line appeared in the control
window "C". The time for reaching the determined color is at least
15 minutes and a maximum of 20 minutes.
• A positive result is the appearance of two red lines of any
intensity: one in the "C" control window, the other in the "T"
result window.
• A negative result is the appearance of one line only in window
"C".
• Invalid result is the absence of a line in the control window "C",
even if there is a red line in the result window "T".
9. Results of the sensitivity evaluation of the “TOYO Anti‐HCV Test
WD/S/P” by seroconversion panel
“HCV AccuVert SPanel Modified PHV 911(M) 0610‐0206”
HCV
AccuVert
Seroconversi
on Panel
Modified
PHV 911(M)
0610‐0206
Name of the test‐system
RT
«TOYO Anti‐
HCV
Test WD/S/P»
c ϵ
EIA
Dia Pro
Diagnostic
HCV Ab
c ϵ
RT
SD Bio Line
HCV (Multi)
PreQ ‐
WHO
RT
Human
Hexagon
HCV
c ϵ
RT
NADAL
HCV‐Test
(test
device)
non ‐ c ϵ
RNA
QIAGEN
Artus HCV
RT‐PCR
Kits
c ϵ
PHV911‐02 Neg 0.1 Neg Neg Neg Neg Pos
PHV911‐03 Pos 1.5 Pos Pos Neg Neg Pos
PHV911‐04 Pos 11,6 Pos Pos Pos Neg Pos
PHV911‐05 Pos 12,1 Pos Pos Pos Neg Pos
12. Sample
No.
EIA WB/IB RT
Dia Pro
Diagnos
tic
HCV Ab
c ϵ
s/co
ДС‐
ИФА‐
HCV‐
АГ/АТ
s/co
INNO
LIA HCV
Score
c ϵ
Bio‐Rad
Deciscan
HCV PLUS
c ϵ
RT
SD Bio
Line
HCV
(Multi)
preQ‐
WHO
RT
Human
Hexagon
HCV
c ϵ
RT
NADAL
HCV‐Test
(test
device)
non c ϵ
RT
«TOYO
Anti‐HCV
Test
WD/S/P»
c ϵ
PHV207‐22 2,8
Pos
4,4
Pos
IND
One line
NS3+
Neg Neg Neg Neg Neg
Results of evaluation of the sample No. PHV207‐22 “Anti‐HCV”
from “Mixed Titer Performance Panel PHV207” in Republican
Scientific Practical Center for Quality Control of Laboratory
Diagnostics of Infectious Diseases of the Ministry of Health of
the Kyrgyz Republic
13. Discussion on sample #PHV207‐22 results
• Based on the results presented on last two slides, we the authors
believe:
‐ in the case of sample # PHV207‐22, a reaction to the single NS3 HCV
protein band takes place. That result is indeterminate (definitely not
positive) by test Ortho RIBA 3.0
• Thus, the difference between the ELISA and EDT testing methods was
demonstrated.
• The difference can possibly be due to the difference in membrane‐
based (nitrocellulose) and plastic‐based technology.
• Over all this particular specimen were positive (6 out of 10) by the
plastic‐based tests, the membrane tests have no positive result (0 of 5).
Even with a small sample size the difference is significant (P <0.05)
• Surely, suchlike blood can not be used for Blood Transfusion!
Nevertheless, there are no grounds to treat this patient follow the
current testing result from hepatitis C!
14. Conclusion:
1. Valid results were received in 100% cases :
– for “TOYO Anti‐HCV Test WD/S/P” 200 out of 200.
2. Sensitivity of the “TOYO Anti‐HCV Test WD/S/P”, Lot HC021802 test
cassettes is 100% for all positive samples, except for No. 02 from 4
samples of seroconversion panels. Specificity is 100%.
3. The comparative assessment of the sensitivity of the tests “anti‐HCV
Test WD/S/P" for "HCV AccuVert Seroconversion Panel" with RT of 3
manufacturers showed comparable results
4. One serum of seroconversion panel was positive by EECA producer
RDT that indicate exceeded the sensitivity of EECA RDT in comparison
with two Western manufacturers and exceeded CE certificate ELISA
used as assessment test for validation.
5. The RNA of HCV was determined by PCR in all 4 samples of the “HCV
AccuVert Seroconversion Panel Modified”.
6. Special sample #PHV207‐22 testing indicated relatively lower fuls
positivity rate by RDT used